Developer docs
API playgroundTry for free, no card

Search company profiles

Prokidney

Full company profile

uuid0000mm9

Namestring
Prokidney
Legal namestring
ProKidney Corp.
Websiteurl
prokidney.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

ProKidney Corp. (NASDAQ: PROK) is a late clinical-stage biotechnology company founded in 2015 and headquartered in Winston-Salem, North Carolina. It is developing rilparencel (also known as REACT), a first-of-its-kind, proprietary autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes who are at high risk of kidney failure. The therapy is administered via a novel bilateral kidney injection procedure and has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. Phase 2 REGEN-007 results demonstrated a statistically significant 78% improvement in annual eGFR slope decline (p<0.001) with no rilparencel-related serious adverse events, and the FDA has agreed to use eGFR slope as the primary endpoint for accelerated approval in the ongoing Phase 3 PROACT 1 study, with pivotal topline data anticipated in Q2 2027.

The company became publicly traded in July 2022 through a business combination with Social Capital Suvretta Holdings Corp. III (SPAC), and completed domestic redomiciliation to Delaware in July 2025. ProKidney operates a single-asset pipeline and is currently pre-commercial — Q2 2026 revenue was $150,000 and FY 2025 revenue was $893,000, with no approved product and no disclosed pricing model. The addressable population is approximately 1 million+ Stage 3b/4 CKD patients in the U.S., with over 135,000 progressing to dialysis annually; the broader CKD market across the seven major markets was approximately $4.8 billion in 2024. Cash and equivalents stood at $181.6 million as of Q2 2026, with management's stated runway into mid-2027, and the company has recently built out a commercial leadership team (Chief Commercial Officer in March 2026, Chief Technical Officer in June 2026) to prepare for a prospective U.S. direct launch.

Short descriptiontext

ProKidney is a late clinical-stage biotechnology company developing rilparencel, a first-in-class autologous cell therapy that preserves kidney function in advanced CKD patients with type 2 diabetes, currently in Phase 3 trials with pivotal results expected in Q2 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWinston Salem, United States
HQ citystring
Winston Salem
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autologous cell therapy, chronic kidney disease, regenerative medicine, biopharmaceutical products, cell therapy pipeline
Industry1 code
PRIMARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy
Social media profiles1 record
Revenue model1 record
1Pre-commercial / Clinical Stage Revenue
TypeOne Time License
Description

ProKidney is a late clinical-stage company without an approved commercial product. Current revenue is minimal, derived from limited sources while the company advances rilparencel through Phase 3 clinical trials toward potential commercialization. Revenue for Q2 2026 was $150,000.

quiverquant.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1REACT
Description

Renal Autologous Cell Therapy - the proprietary autologous cell therapy technology platform for rilparencel

investors.prokidney.com
+1 more record
Core offering1 text field

ProKidney is developing rilparencel (REACT®), a first-of-its-kind proprietary autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes who are at high risk of kidney failure. The therapy is administered via bilateral kidney injection using the patient's own cells and is being evaluated in the Phase 3 PROACT 1 trial. The product has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, with pivotal topline results anticipated in Q2 2027.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 78% improvement in annual eGFR slope decline in Phase 2 REGEN-007 Group 1 patients (n=24) with advanced CKD and diabetes (p<0.001)
+2 more records
Product overview1 text field

ProKidney is a late clinical-stage biotechnology company with a single core product focus: rilparencel (also known as REACT®), a first-in-class autologous cell therapy. The company is evaluating rilparencel in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes at high risk of kidney failure. The product pipeline consists of this one lead candidate, which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.

Product and service1 record
1Rilparencel (also known as REACT®)
CategoryCell Therapy
Description

Rilparencel (REACT®) is ProKidney's lead product candidate — a first-of-its-kind, proprietary autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes who are at high risk of kidney failure. The therapy is administered via bilateral kidney injection using the patient's own cells and has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. It is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study, with pivotal topline results anticipated in Q2 2027.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Vertex is the leading commercial-stage cell and gene therapy biotech (CASGEVY), making it the most relevant direct comparator for a cell-therapy platform biotech approaching its first commercial launch.

TypeDirect peer
Description

Vericel markets autologous cell therapies (MACI, Epicel) and operates a personalized cell-therapy commercial model directly comparable to ProKidney's planned autologous kidney therapy launch.

3bluebird bio
TypeDirect peer
Description

bluebird bio develops and commercializes autologous gene and cell therapies, sharing manufacturing complexity, regulatory pathway, and commercial-launch dynamics with ProKidney's rilparencel.

TypeBroad incumbent
Description

AstraZeneca markets Farxiga (dapagliflozin), an SGLT2 inhibitor with a major CKD label, and is the broad incumbent defining standard-of-care treatments that ProKidney would compete with or complement.

TypeBroad incumbent
Description

Bayer markets Kerendia (finerenone), the first non-steroidal MRA approved to slow CKD progression in T2D, the most direct approved small-molecule competitor to rilparencel.

TypeBroad incumbent
Description

The Lilly/BI partnership markets Jardiance (empagliflozin), also indicated to slow CKD progression, and represents the large-pharma incumbent whose primary-care channel reach sets the bar for any new CKD therapy.

TypeEmerging player
Description

Akebia is a nephrology-focused specialty biotech with CKD and anemia-of-CKD assets, making it a comparable smaller commercial/specialty pharma competitor in the same physician channel.

TypeEmerging player
Description

Ardelyx commercializes kidney-disease therapies (Xphozah, tenapanor) and shares a nephrology specialty commercial focus with ProKidney's planned CKD launch.

TypeEmerging player
Description

Mesoblast develops allogeneic cellular medicines for inflammatory and cardiovascular conditions, providing a relevant cell-therapy comparator for manufacturing scale-up, regulatory path, and pricing.

TypeEmerging player
Description

Chinook was a CKD-focused biotech acquired by Novartis in 2023; it serves as the bellwether for strategic value of late-stage CKD assets and validates large-pharma appetite for the indication.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Prokidney

Cell Therapyprokidney.com

ProKidney is a late clinical-stage biotechnology company developing rilparencel, a first-in-class autologous cell therapy that preserves kidney function in advanced CKD patients with type 2 diabetes, currently in Phase 3 trials with pivotal results expected in Q2 2027.

What Prokidney does

ProKidney Corp. (NASDAQ: PROK) is a late clinical-stage biotechnology company founded in 2015 and headquartered in Winston-Salem, North Carolina. It is developing rilparencel (also known as REACT), a first-of-its-kind, proprietary autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes who are at high risk of kidney failure. The therapy is administered via a novel bilateral kidney injection procedure and has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. Phase 2 REGEN-007 results demonstrated a statistically significant 78% improvement in annual eGFR slope decline (p<0.001) with no rilparencel-related serious adverse events, and the FDA has agreed to use eGFR slope as the primary endpoint for accelerated approval in the ongoing Phase 3 PROACT 1 study, with pivotal topline data anticipated in Q2 2027.

The company became publicly traded in July 2022 through a business combination with Social Capital Suvretta Holdings Corp. III (SPAC), and completed domestic redomiciliation to Delaware in July 2025. ProKidney operates a single-asset pipeline and is currently pre-commercial — Q2 2026 revenue was $150,000 and FY 2025 revenue was $893,000, with no approved product and no disclosed pricing model. The addressable population is approximately 1 million+ Stage 3b/4 CKD patients in the U.S., with over 135,000 progressing to dialysis annually; the broader CKD market across the seven major markets was approximately $4.8 billion in 2024. Cash and equivalents stood at $181.6 million as of Q2 2026, with management's stated runway into mid-2027, and the company has recently built out a commercial leadership team (Chief Commercial Officer in March 2026, Chief Technical Officer in June 2026) to prepare for a prospective U.S. direct launch.

Prokidney firmographics

Firmographics
Name
Prokidney
Legal name
ProKidney Corp.
Website
https://prokidney.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
ProKidney is a late clinical-stage biotechnology company developing rilparencel, a first-in-class autologous cell therapy that preserves kidney function in advanced CKD patients with type 2 diabetes, currently in Phase 3 trials with pivotal results expected in Q2 2027.
Ownership category
akta.pro rank

Prokidney industry classification

Industry
Product category
Cell Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals

Keywords

  • Autologous cell therapy
  • Chronic kidney disease
  • Regenerative medicine
  • Biopharmaceutical products
  • Cell therapy pipeline

Where Prokidney is headquartered

Location

Headquarters

HQ city
Winston Salem
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Prokidney business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pre-commercial / Clinical Stage Revenue: ProKidney is a late clinical-stage company without an approved commercial product. Current revenue is minimal, derived from limited sources while the company advances rilparencel through Phase 3 clinical trials toward potential commercialization. Revenue for Q2 2026 was $150,000.

Distribution channels1 record

Marketing channels3 records

Prokidney product offering

Product offering

Core offering

ProKidney is developing rilparencel (REACT®), a first-of-its-kind proprietary autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes who are at high risk of kidney failure. The therapy is administered via bilateral kidney injection using the patient's own cells and is being evaluated in the Phase 3 PROACT 1 trial. The product has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, with pivotal topline results anticipated in Q2 2027.

Product overview

ProKidney is a late clinical-stage biotechnology company with a single core product focus: rilparencel (also known as REACT®), a first-in-class autologous cell therapy. The company is evaluating rilparencel in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes at high risk of kidney failure. The product pipeline consists of this one lead candidate, which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.

Differentiator

Problem solved

Functional benefit

Brands

  • REACT: Renal Autologous Cell Therapy - the proprietary autologous cell therapy technology platform for rilparencel
  • Rilparencel

Products and services

  • Rilparencel (also known as REACT®) Rilparencel (REACT®) is ProKidney's lead product candidate — a first-of-its-kind, proprietary autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes who are at high risk of kidney failure. The therapy is administered via bilateral kidney injection using the patient's own cells and has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. It is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study, with pivotal topline results anticipated in Q2 2027.

Quantifiable outcome

  • 78% improvement in annual eGFR slope decline in Phase 2 REGEN-007 Group 1 patients (n=24) with advanced CKD and diabetes (p<0.001)
  • +2 more outcomes

Companies that use Prokidney

Customer profile

Segments1 record

Ideal customer profiles1 record

Prokidney technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Prokidney partnerships and signals

Strategic signal

Scale indicators10 records

Recent moves9 records

Expansion highlights4 records

Prokidney competitors and assessment

Company assessment

Direct peers

  • Vertex Pharmaceuticals: Vertex is the leading commercial-stage cell and gene therapy biotech (CASGEVY), making it the most relevant direct comparator for a cell-therapy platform biotech approaching its first commercial launch.
  • Vericel Corporation: Vericel markets autologous cell therapies (MACI, Epicel) and operates a personalized cell-therapy commercial model directly comparable to ProKidney's planned autologous kidney therapy launch.
  • bluebird bio: bluebird bio develops and commercializes autologous gene and cell therapies, sharing manufacturing complexity, regulatory pathway, and commercial-launch dynamics with ProKidney's rilparencel.

Broad incumbents

  • AstraZeneca: AstraZeneca markets Farxiga (dapagliflozin), an SGLT2 inhibitor with a major CKD label, and is the broad incumbent defining standard-of-care treatments that ProKidney would compete with or complement.
  • Bayer: Bayer markets Kerendia (finerenone), the first non-steroidal MRA approved to slow CKD progression in T2D, the most direct approved small-molecule competitor to rilparencel.
  • Eli Lilly / Boehringer Ingelheim: The Lilly/BI partnership markets Jardiance (empagliflozin), also indicated to slow CKD progression, and represents the large-pharma incumbent whose primary-care channel reach sets the bar for any new CKD therapy.

Emerging players

  • Akebia Therapeutics: Akebia is a nephrology-focused specialty biotech with CKD and anemia-of-CKD assets, making it a comparable smaller commercial/specialty pharma competitor in the same physician channel.
  • Ardelyx: Ardelyx commercializes kidney-disease therapies (Xphozah, tenapanor) and shares a nephrology specialty commercial focus with ProKidney's planned CKD launch.
  • Mesoblast: Mesoblast develops allogeneic cellular medicines for inflammatory and cardiovascular conditions, providing a relevant cell-therapy comparator for manufacturing scale-up, regulatory path, and pricing.
  • Chinook Therapeutics (acquired by Novartis): Chinook was a CKD-focused biotech acquired by Novartis in 2023; it serves as the bellwether for strategic value of late-stage CKD assets and validates large-pharma appetite for the indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Prokidney social profiles

Digital presence

Prokidney compliance and trust

Trust signal

Compliance1 record

Prokidney financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Prokidney leadership team

Management profile

Number of profiles

Profiles7 records

Prokidney subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Prokidney funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Prokidney M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Prokidney

What does Prokidney do?

ProKidney is developing rilparencel (REACT®), a first-of-its-kind proprietary autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes who are at high risk of kidney failure. The therapy is administered via bilateral kidney injection using the patient's own cells and is being evaluated in the Phase 3 PROACT 1 trial. The product has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, with pivotal topline results anticipated in Q2 2027.

Is Prokidney a public or private company?

Prokidney is a public company. It is classified as public and is currently operating.

When was Prokidney founded?

Prokidney was founded in 2015. It employs 101 to 250 people.

Where is Prokidney based?

Prokidney is headquartered in Winston Salem, United States, in the North America region.

How does Prokidney make money?

One revenue line is on record: pre-commercial / Clinical Stage Revenue.

Who are Prokidney's main competitors?

Direct peers on record are Vertex Pharmaceuticals, Vericel Corporation and bluebird bio. Broad incumbents are AstraZeneca, Bayer and Eli Lilly / Boehringer Ingelheim. Emerging players are Akebia Therapeutics, Ardelyx, Mesoblast and Chinook Therapeutics (acquired by Novartis).

Does Prokidney have an API?

No public API is recorded for Prokidney.

What industry is Prokidney in?

Prokidney's product category is Cell Therapy. Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comProKidney at guggenheim healthcare innovation conference: late-stage kidney pushProKidney outlined its late-stage plan for rilparencel at the Guggenheim Healthcare Innovation Conference, targeting patients with advanced chronic kidney disease and diabetes. The company expects to finish Phase III enrollment in Q1 2027 and report an accelerated approval readout in Q2 2027, with $142 million in cash funding operations through mid-2027.American Banking and Market NewsCitigroup Has Lowered Expectations for ProKidney (NASDAQ:PROK) Stock PriceCitigroup lowered its ProKidney price target to $8.00, citing a "buy" rating. The stock missed Q2 earnings estimates with -$0.15 EPS versus -$0.14 expected, and insiders sold 757,164 shares over three months. Analysts forecast a -0.51 EPS for the current fiscal year.TradingViewProKidney Establishes $200 Million At-the-Market Stock Offering With JefferiesProKidney entered an at-the-market sales agreement with Jefferies to offer up to $200 million of Class A common stock. Jefferies may receive up to 3.0% of gross proceeds plus expense reimbursement. The company is not obligated to sell shares and may suspend the offering at any time.MarketBeatProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500ProKidney said it will report top-line results from the interim analysis of its Phase III PROACT 1 study in Q2 2027, after enrollment surpassed 500 patients. The company previously guided to complete enrollment in 2026, but recruitment increased screening activity across 80+ sites. The trial targets a 1.5 mL/min eGFR slope difference, aiming for a 50% reduction in kidney-function decline.Seeking AlphaProKidney Corp. (PROK) Discusses Rilparencel Mechanism and Role in Advanced Chronic Kidney Disease TranscriptProKidney Corp. held a webcast on October 27, 2026, with CEO Bruce Culleton and R&D head Anthony Conway discussing rilparencel's mechanism and potential role in advanced chronic kidney disease. The company aims to extend life without dialysis for patients with advanced CKD.Quiver QuantitativeProKidney Corp. to Host Virtual KOL Event on Rilparencel and Advanced CKD Research Following ASN Kidney Week 2026 | PROK Stock NewsProKidney Corp. will host a virtual KOL event on October 27, 2026, featuring Dr. Katherine Tuttle and Dr. Anthony Conway to discuss rilparencel's mechanism of action from ASN Kidney Week 2026. The event includes a Q&A and corporate update, with Dr. Tuttle providing clinical insights on advanced CKD and type 2 diabetes.Business & FinancialProkidney To Host Virtual KOL Event To Recap Mechanism Of Action Data Presented At ASN Kidney Week And Provide A Corporate UpdateProKidney will host a virtual KOL event featuring nephrologist Katherine Tuttle and company management to recap rilparencel's mechanism of action data from ASN Kidney Week 2026. The event will also cover the drug's potential role in advanced CKD and type 2 diabetes, with a corporate update and Q&A.FinancialContent Business PageProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate UpdateProKidney Corp. will host a virtual KOL event on October 27, 2026, to recap rilparencel's mechanism of action data from ASN Kidney Week 2026 and provide a corporate update. The event features nephrology leader Katherine Tuttle, MD, and management, with a Q&A session. The company's Phase 3 REGEN-006 (PROACT 1) trial for advanced CKD and type 2 diabetes is ongoing.Ticker ReportProKidney (NASDAQ:PROK) Shares Down 6% – What’s Next?ProKidney Corp. shares fell 6% on Tuesday, trading as low as $1.53. The company reported a quarterly loss of $0.15 per share, missing the consensus estimate of $0.14, and revenue of $0.15 million versus $0.19 million expected. Analysts have a consensus price target of $12.00.Markets DailyProKidney (NASDAQ:PROK) vs. uniQure (NASDAQ:QURE) Financial SurveyProKidney beats uniQure on 9 of 14 financial factors, including profitability and analyst recommendations. ProKidney has a higher potential upside (716.33%) versus uniQure's 156.21%, and its stock is more volatile. The comparison covers net margins, revenue, and institutional ownership.